云顶新耀任命康岚女士为董事会成员
22 déc. 2020 07h12 HE
|
Everest Medicines
中国上海, Dec. 22, 2020 (GLOBE NEWSWIRE) -- 家专注于创新药开发及商业化的生物制药公司，致力于满足中国（含香港、澳门以及台湾地区）及亚洲其他市场尚未满足的医疗需求，今天宣布任命康岚女士为公司董事会非执行董事。康女士拥有超过二十年的生命科学行业经验，在跨国公司中积累了丰富的专业知识，并领导了重要的业务发展和运营职能。 ...
Everest Medicines Appoints Lan Kang to Board of Directors
22 déc. 2020 07h12 HE
|
Everest Medicines
SHANGHAI, China, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...
云顶新耀公布Trodelvy™ (sacituzumab govitecan)用于治疗转移性乳腺癌的亚洲3期临床试验完成首例患者给药
09 déc. 2020 03h30 HE
|
Everest Medicines
中国上海, Dec. 09, 2020 (GLOBE NEWSWIRE) -- 云顶新耀（HKEX 1952.HK），一家专注于创新药开发及商业化的生物制药公司，致力于满足中国（含香港、澳门以及台湾地区）及亚洲其他市场尚未满足的医疗需求，今天公布Trodelvy™ (sacituzumab...
Everest Medicines Announces First Patient Dosed in Phase 3 Registration Asian Study of TrodelvyTM (sacituzumab govitecan) for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
09 déc. 2020 03h30 HE
|
Everest Medicines
SHANGHAI, China, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that...
云顶新耀公布国家药品监督管理局药品审评中心公示Nefecon为拟突破性治疗品种
01 déc. 2020 18h30 HE
|
Everest Medicines
中国上海, Dec. 02, 2020 (GLOBE NEWSWIRE) -- 云顶新耀 (HKEX 1952.HK)， 是一家专注于创新药研发及商业化的生物制药公司，致力于满足大中华区及亚洲其它市场未被满足的医疗需求，今日公布国家药品监督管理局药品审评中心在其官网上公示Nefecon为拟突破性治疗品种，Nefecon是云顶新耀引进开发用于治疗IgA肾病的创新药物。 Nefecon...
Everest Medicines Announces The China Center for Drug Evaluation, National Medical Products Administration Recommends Breakthrough Therapy Designation for Nefecon for the Treatment of IgA Nephropathy
01 déc. 2020 18h30 HE
|
Everest Medicines
SHANGHAI, China, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that...
云顶新耀公布其合作伙伴Calliditas Therapeutics报告了NeflgArd关键性3期临床试验关键数据获得良好结果
09 nov. 2020 18h45 HE
|
Everest Medicines
中国，上海, Nov. 10, 2020 (GLOBE NEWSWIRE) -- 云顶新耀(HKEX 1952.HK)，是一家专注于创新药研发及商业化的生物制药公司，致力于满足大中华区及其它亚洲市场未被满足的医疗需求，今日公司公布了其合作伙伴Calliditas Therapeutics AB(“Calliditas”，纳斯达克股票代码：CALT)报告了全球3期临床试验NefIgArd...
Everest Medicines Announces that Licensing Partner Calliditas Therapeutics has Reported Positive Topline Results from Pivotal Phase 3 NefIgArd Trial
09 nov. 2020 18h45 HE
|
Everest Medicines
SHANGHAI, China, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that...
云顶新耀公布Trodelvy™ (sacituzumab govitecan)用于治疗转移性三阴性乳腺癌的2b期注册临床试验完成首例患者给药
03 nov. 2020 05h38 HE
|
Everest Medicines
中国上海, Nov. 03, 2020 (GLOBE NEWSWIRE) -- 云顶新耀（Everest Medicines，HKEX 1952.HK），一家专注于创新药开发及商业化的生物制药公司，致力于满足中国（含香港、澳门以及台湾地区）及其它亚洲市场未被满足的医疗需求，今天宣布在中国开展的TrodelvyTM（sacituzumab govitecan,...
Everest Medicines Announces First Patient Dosed in its Phase 2b Registration Clinical Trial of Trodelvy™ (sacituzumab govitecan) for Metastatic Triple-Negative Breast Cancer in China
03 nov. 2020 05h38 HE
|
Everest Medicines
SHANGHAI, China, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that...